UniProt functional annotation for Q13093



	UniProt functional annotation for Q13093

UniProt code: Q13093.

Organism: Homo sapiens (Human).

Taxonomy: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

Function: Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:7700381, PubMed:8624782, PubMed:2040620, PubMed:16371369, PubMed:17090529, PubMed:10066756). At the lipid- aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:2040620, PubMed:10504265). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position (PubMed:2040620). Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups (PubMed:2040620, PubMed:8624782). Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl- 2-acetyl-sn-glycero-3-phosphocholine), a potent proinflammatory signaling lipid that acts through PTAFR on various innate immune cells (PubMed:10504265, PubMed:10066756, PubMed:7592717, PubMed:11590221, PubMed:7700381, PubMed:18434304, PubMed:16371369, PubMed:8675689, PubMed:8624782). Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled proinflammatory effects (PubMed:2040620, PubMed:7700381). As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall (PubMed:17090529). Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage (PubMed:16371369). {ECO:0000269|PubMed:10066756, ECO:0000269|PubMed:10504265, ECO:0000269|PubMed:11590221, ECO:0000269|PubMed:16371369, ECO:0000269|PubMed:17090529, ECO:0000269|PubMed:18434304, ECO:0000269|PubMed:2040620, ECO:0000269|PubMed:7592717, ECO:0000269|PubMed:7700381, ECO:0000269|PubMed:8624782, ECO:0000269|PubMed:8675689}.

Catalytic activity: Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- alkyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:17777, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707; EC=3.1.1.47; Evidence={ECO:0000269|PubMed:10066756, ECO:0000269|PubMed:16371369, ECO:0000269|PubMed:18434304, ECO:0000269|PubMed:7592717, ECO:0000269|PubMed:7700381, ECO:0000269|PubMed:8624782, ECO:0000269|PubMed:8675689}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17778; Evidence={ECO:0000305|PubMed:8675689};

Catalytic activity: Reaction=1-O-decyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- decyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41376, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78108, ChEBI:CHEBI:78109; Evidence={ECO:0000269|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41377; Evidence={ECO:0000305|PubMed:10504265};

Catalytic activity: Reaction=1-O-dodecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- dodecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41372, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78103, ChEBI:CHEBI:78104; Evidence={ECO:0000269|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41373; Evidence={ECO:0000305|PubMed:10504265};

Catalytic activity: Reaction=1-O-tetradecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-tetradecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41368, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78101, ChEBI:CHEBI:78102; Evidence={ECO:0000269|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41369; Evidence={ECO:0000305|PubMed:10504265};

Catalytic activity: Reaction=1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-hexadecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:40479, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:44811, ChEBI:CHEBI:64496; Evidence={ECO:0000269|PubMed:10504265, ECO:0000269|PubMed:11590221}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40480; Evidence={ECO:0000305|PubMed:10504265};

Catalytic activity: Reaction=1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-octadecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41183, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:52450, ChEBI:CHEBI:75216; Evidence={ECO:0000269|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41184; Evidence={ECO:0000305|PubMed:10504265};

Catalytic activity: Reaction=1-hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- hexadecanoyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41203, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:72998, ChEBI:CHEBI:75219; Evidence={ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41204; Evidence={ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-propionyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + propanoate; Xref=Rhea:RHEA:41191, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17272, ChEBI:CHEBI:72998, ChEBI:CHEBI:77831; Evidence={ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41192; Evidence={ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-butanoyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + butanoate + H(+); Xref=Rhea:RHEA:41195, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17968, ChEBI:CHEBI:72998, ChEBI:CHEBI:77832; Evidence={ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41196; Evidence={ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-pentanoyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + pentanoate; Xref=Rhea:RHEA:41199, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:31011, ChEBI:CHEBI:72998, ChEBI:CHEBI:77833; Evidence={ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41200; Evidence={ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-glutaroyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + glutarate + H(+); Xref=Rhea:RHEA:41159, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30921, ChEBI:CHEBI:72998, ChEBI:CHEBI:77756; Evidence={ECO:0000269|PubMed:2040620, ECO:0000269|PubMed:7700381}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41160; Evidence={ECO:0000305|PubMed:2040620, ECO:0000305|PubMed:7700381};

Catalytic activity: Reaction=1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 5-oxopentanoate + H(+); Xref=Rhea:RHEA:40483, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:16120, ChEBI:CHEBI:72998, ChEBI:CHEBI:77890; Evidence={ECO:0000269|PubMed:16371369, ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40484; Evidence={ECO:0000305|PubMed:16371369, ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 9-oxononanoate + H(+); Xref=Rhea:RHEA:41179, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:61042, ChEBI:CHEBI:72998, ChEBI:CHEBI:77812; Evidence={ECO:0000269|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41180; Evidence={ECO:0000305|PubMed:2040620};

Catalytic activity: Reaction=1-hexadecanoyl-2-[9-hydroperoxy-(10E-octadecenoyl)]-sn- glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3- phosphocholine + 9-hydroperoxy-10E-octadecenoate + H(+); Xref=Rhea:RHEA:41151, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:77753, ChEBI:CHEBI:77754; Evidence={ECO:0000269|PubMed:16371369, ECO:0000269|PubMed:17090529}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41152; Evidence={ECO:0000305|PubMed:16371369, ECO:0000305|PubMed:17090529};

Catalytic activity: Reaction=1-hexadecanoyl-2-(10-hydroperoxy-8E-octadecenoyl)-sn-glycero- 3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 10-hydroperoxy-8E-octadecenoate + H(+); Xref=Rhea:RHEA:41155, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:77749, ChEBI:CHEBI:77755; Evidence={ECO:0000269|PubMed:17090529}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41156; Evidence={ECO:0000305|PubMed:17090529};

Biophysicochemical properties: Kinetic parameters: KM=12.5 uM for 1-hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; KM=3.1 uM for 1-hexadecanoyl-2-propionyl-sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; KM=7.9 uM for 1-hexadecanoyl-2-butanoyl-sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; KM=6.2 uM for 1-hexadecanoyl-2-pentanoyl-sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; KM=11.3 uM for 1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3- phosphocholine {ECO:0000269|PubMed:2040620}; KM=15.5 uM for 1-hexadecanoyl-2-(9-oxononanoyl)-sn-glycero-3- phosphocholine {ECO:0000269|PubMed:2040620}; KM=43.1 uM for 1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3- phosphocholine {ECO:0000269|PubMed:16371369}; Vmax=167 umol/h/mg enzyme toward 1-hexadecanoyl-2-acetyl-sn-glycero- 3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=36.1 umol/h/mg enzyme toward 1-hexadecanoyl-2-propionyl-sn- glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=43.4 umol/h/mg enzyme toward 1-hexadecanoyl-2-butanoyl-sn- glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=42.2 umol/h/mg enzyme toward 1-hexadecanoyl-2-pentanoyl-sn- glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=100 umol/h/mg enzyme toward 1-hexadecanoyl-2-(5-oxopentanoyl)- sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=98.4 umol/h/mg enzyme toward 1-hexadecanoyl-2-(9-oxononanoyl)- sn-glycero-3-phosphocholine {ECO:0000269|PubMed:2040620}; Vmax=5.0 umol/min/mg enzyme toward 1-hexadecanoyl-2-(5-oxopentanoyl)- sn-glycero-3-phosphocholine {ECO:0000269|PubMed:16371369};

Subcellular location: Secreted, extracellular space {ECO:0000269|PubMed:10066756, ECO:0000269|PubMed:11590221, ECO:0000269|PubMed:12821559, ECO:0000269|PubMed:18434304}. Note=Associates with both LDL and HDL particles in plasma (PubMed:11590221, PubMed:12821559, PubMed:18434304, PubMed:10066756). Mainly associates with proinflammatory electronegative LDL particles (PubMed:12821559). {ECO:0000269|PubMed:10066756, ECO:0000269|PubMed:11590221, ECO:0000269|PubMed:12821559, ECO:0000269|PubMed:18434304}.

Tissue specificity: Plasma (PubMed:11590221, PubMed:12821559). Secreted by macrophages (at protein level) (PubMed:11590221). {ECO:0000269|PubMed:11590221, ECO:0000269|PubMed:12821559}.

Induction: Up-regulated upon monocyte differentiation toward macrophage lineage. {ECO:0000269|PubMed:11590221}.

Ptm: N-glycosylated. Macrophage-derived PLA2G7 carries sialylated complex-type N-glycans that hinder its binding to HDL particles. {ECO:0000269|PubMed:11590221}.

Disease: Platelet-activating factor acetylhydrolase deficiency (PAFAD) [MIM:614278]: An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. It can be associated with several disease states including inflammatory gastrointestinal disorders, asthma and atopy. Asthmatic individuals with PAFAD may manifest aggravated respiratory symptoms. {ECO:0000269|PubMed:8675689, ECO:0000269|PubMed:9245731, ECO:0000269|PubMed:9412624, ECO:0000269|PubMed:9472966, ECO:0000269|PubMed:9759612}. Note=The disease is caused by variants affecting the gene represented in this entry.

Disease: Asthma (ASTHMA) [MIM:600807]: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi. {ECO:0000269|PubMed:10733466}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.

Disease: Atopic hypersensitivity (ATOPY) [MIM:147050]: A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. {ECO:0000269|PubMed:10733466}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.

Similarity: Belongs to the AB hydrolase superfamily. Lipase family. {ECO:0000305}.

Annotations taken from UniProtKB at the EBI.


Organism:		Homo sapiens (Human).
Taxonomy:		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.



Function:		Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:7700381, PubMed:8624782, PubMed:2040620, PubMed:16371369, PubMed:17090529, PubMed:10066756). At the lipid- aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:2040620, PubMed:10504265). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position (PubMed:2040620). Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups (PubMed:2040620, PubMed:8624782). Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl- 2-acetyl-sn-glycero-3-phosphocholine), a potent proinflammatory signaling lipid that acts through PTAFR on various innate immune cells (PubMed:10504265, PubMed:10066756, PubMed:7592717, PubMed:11590221, PubMed:7700381, PubMed:18434304, PubMed:16371369, PubMed:8675689, PubMed:8624782). Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled proinflammatory effects (PubMed:2040620, PubMed:7700381). As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall (PubMed:17090529). Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage (PubMed:16371369). {ECO:0000269\|PubMed:10066756, ECO:0000269\|PubMed:10504265, ECO:0000269\|PubMed:11590221, ECO:0000269\|PubMed:16371369, ECO:0000269\|PubMed:17090529, ECO:0000269\|PubMed:18434304, ECO:0000269\|PubMed:2040620, ECO:0000269\|PubMed:7592717, ECO:0000269\|PubMed:7700381, ECO:0000269\|PubMed:8624782, ECO:0000269\|PubMed:8675689}.


Catalytic activity:		Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- alkyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:17777, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707; EC=3.1.1.47; Evidence={ECO:0000269\|PubMed:10066756, ECO:0000269\|PubMed:16371369, ECO:0000269\|PubMed:18434304, ECO:0000269\|PubMed:7592717, ECO:0000269\|PubMed:7700381, ECO:0000269\|PubMed:8624782, ECO:0000269\|PubMed:8675689}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17778; Evidence={ECO:0000305\|PubMed:8675689};
Catalytic activity:		Reaction=1-O-decyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- decyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41376, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78108, ChEBI:CHEBI:78109; Evidence={ECO:0000269\|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41377; Evidence={ECO:0000305\|PubMed:10504265};
Catalytic activity:		Reaction=1-O-dodecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O- dodecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41372, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78103, ChEBI:CHEBI:78104; Evidence={ECO:0000269\|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41373; Evidence={ECO:0000305\|PubMed:10504265};
Catalytic activity:		Reaction=1-O-tetradecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-tetradecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41368, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:78101, ChEBI:CHEBI:78102; Evidence={ECO:0000269\|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41369; Evidence={ECO:0000305\|PubMed:10504265};
Catalytic activity:		Reaction=1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-hexadecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:40479, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:44811, ChEBI:CHEBI:64496; Evidence={ECO:0000269\|PubMed:10504265, ECO:0000269\|PubMed:11590221}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40480; Evidence={ECO:0000305\|PubMed:10504265};
Catalytic activity:		Reaction=1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- O-octadecyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41183, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:52450, ChEBI:CHEBI:75216; Evidence={ECO:0000269\|PubMed:10504265}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41184; Evidence={ECO:0000305\|PubMed:10504265};
Catalytic activity:		Reaction=1-hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1- hexadecanoyl-sn-glycero-3-phosphocholine + acetate + H(+); Xref=Rhea:RHEA:41203, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30089, ChEBI:CHEBI:72998, ChEBI:CHEBI:75219; Evidence={ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41204; Evidence={ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-propionyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + propanoate; Xref=Rhea:RHEA:41191, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17272, ChEBI:CHEBI:72998, ChEBI:CHEBI:77831; Evidence={ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41192; Evidence={ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-butanoyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + butanoate + H(+); Xref=Rhea:RHEA:41195, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17968, ChEBI:CHEBI:72998, ChEBI:CHEBI:77832; Evidence={ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41196; Evidence={ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-pentanoyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + pentanoate; Xref=Rhea:RHEA:41199, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:31011, ChEBI:CHEBI:72998, ChEBI:CHEBI:77833; Evidence={ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41200; Evidence={ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-glutaroyl-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + glutarate + H(+); Xref=Rhea:RHEA:41159, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30921, ChEBI:CHEBI:72998, ChEBI:CHEBI:77756; Evidence={ECO:0000269\|PubMed:2040620, ECO:0000269\|PubMed:7700381}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41160; Evidence={ECO:0000305\|PubMed:2040620, ECO:0000305\|PubMed:7700381};
Catalytic activity:		Reaction=1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 5-oxopentanoate + H(+); Xref=Rhea:RHEA:40483, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:16120, ChEBI:CHEBI:72998, ChEBI:CHEBI:77890; Evidence={ECO:0000269\|PubMed:16371369, ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40484; Evidence={ECO:0000305\|PubMed:16371369, ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 9-oxononanoate + H(+); Xref=Rhea:RHEA:41179, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:61042, ChEBI:CHEBI:72998, ChEBI:CHEBI:77812; Evidence={ECO:0000269\|PubMed:2040620}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41180; Evidence={ECO:0000305\|PubMed:2040620};
Catalytic activity:		Reaction=1-hexadecanoyl-2-[9-hydroperoxy-(10E-octadecenoyl)]-sn- glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3- phosphocholine + 9-hydroperoxy-10E-octadecenoate + H(+); Xref=Rhea:RHEA:41151, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:77753, ChEBI:CHEBI:77754; Evidence={ECO:0000269\|PubMed:16371369, ECO:0000269\|PubMed:17090529}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41152; Evidence={ECO:0000305\|PubMed:16371369, ECO:0000305\|PubMed:17090529};
Catalytic activity:		Reaction=1-hexadecanoyl-2-(10-hydroperoxy-8E-octadecenoyl)-sn-glycero- 3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + 10-hydroperoxy-8E-octadecenoate + H(+); Xref=Rhea:RHEA:41155, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:77749, ChEBI:CHEBI:77755; Evidence={ECO:0000269\|PubMed:17090529}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41156; Evidence={ECO:0000305\|PubMed:17090529};
Biophysicochemical properties:		Kinetic parameters: KM=12.5 uM for 1-hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; KM=3.1 uM for 1-hexadecanoyl-2-propionyl-sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; KM=7.9 uM for 1-hexadecanoyl-2-butanoyl-sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; KM=6.2 uM for 1-hexadecanoyl-2-pentanoyl-sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; KM=11.3 uM for 1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3- phosphocholine {ECO:0000269\|PubMed:2040620}; KM=15.5 uM for 1-hexadecanoyl-2-(9-oxononanoyl)-sn-glycero-3- phosphocholine {ECO:0000269\|PubMed:2040620}; KM=43.1 uM for 1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3- phosphocholine {ECO:0000269\|PubMed:16371369}; Vmax=167 umol/h/mg enzyme toward 1-hexadecanoyl-2-acetyl-sn-glycero- 3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=36.1 umol/h/mg enzyme toward 1-hexadecanoyl-2-propionyl-sn- glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=43.4 umol/h/mg enzyme toward 1-hexadecanoyl-2-butanoyl-sn- glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=42.2 umol/h/mg enzyme toward 1-hexadecanoyl-2-pentanoyl-sn- glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=100 umol/h/mg enzyme toward 1-hexadecanoyl-2-(5-oxopentanoyl)- sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=98.4 umol/h/mg enzyme toward 1-hexadecanoyl-2-(9-oxononanoyl)- sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:2040620}; Vmax=5.0 umol/min/mg enzyme toward 1-hexadecanoyl-2-(5-oxopentanoyl)- sn-glycero-3-phosphocholine {ECO:0000269\|PubMed:16371369};
Subcellular location:		Secreted, extracellular space {ECO:0000269\|PubMed:10066756, ECO:0000269\|PubMed:11590221, ECO:0000269\|PubMed:12821559, ECO:0000269\|PubMed:18434304}. Note=Associates with both LDL and HDL particles in plasma (PubMed:11590221, PubMed:12821559, PubMed:18434304, PubMed:10066756). Mainly associates with proinflammatory electronegative LDL particles (PubMed:12821559). {ECO:0000269\|PubMed:10066756, ECO:0000269\|PubMed:11590221, ECO:0000269\|PubMed:12821559, ECO:0000269\|PubMed:18434304}.
Tissue specificity:		Plasma (PubMed:11590221, PubMed:12821559). Secreted by macrophages (at protein level) (PubMed:11590221). {ECO:0000269\|PubMed:11590221, ECO:0000269\|PubMed:12821559}.
Induction:		Up-regulated upon monocyte differentiation toward macrophage lineage. {ECO:0000269\|PubMed:11590221}.
Ptm:		N-glycosylated. Macrophage-derived PLA2G7 carries sialylated complex-type N-glycans that hinder its binding to HDL particles. {ECO:0000269\|PubMed:11590221}.
Disease:		Platelet-activating factor acetylhydrolase deficiency (PAFAD) [MIM:614278]: An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. It can be associated with several disease states including inflammatory gastrointestinal disorders, asthma and atopy. Asthmatic individuals with PAFAD may manifest aggravated respiratory symptoms. {ECO:0000269\|PubMed:8675689, ECO:0000269\|PubMed:9245731, ECO:0000269\|PubMed:9412624, ECO:0000269\|PubMed:9472966, ECO:0000269\|PubMed:9759612}. Note=The disease is caused by variants affecting the gene represented in this entry.
Disease:		Asthma (ASTHMA) [MIM:600807]: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi. {ECO:0000269\|PubMed:10733466}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.
Disease:		Atopic hypersensitivity (ATOPY) [MIM:147050]: A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. {ECO:0000269\|PubMed:10733466}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.
Similarity:		Belongs to the AB hydrolase superfamily. Lipase family. {ECO:0000305}.